Antigrippin ANVI, capsules 20 pcs

Pharmacological action – antipyretic, analgesic, analgesic, antihistamine, angioprotective, antipyretic, anti-inflammatory.

Antigrippin ANVI is a drug of combined composition.

Acetylsalicylic acid is an analgesic, antipyretic and anti-inflammatory agent; inhibits platelet aggregation.

Ascorbic acid plays an important role in the regulation of redox processes, carbohydrate metabolism, blood coagulation, tissue regeneration, helps improve the body’s resistance.

Rutoside (rutin) is an angioprotector. It reduces capillary permeability, reduces swelling and inflammation, strengthens the vascular wall. Inhibits aggregation and increases the degree of deformation of red blood cells.

Sodium metamizole has analgesic, antipyretic and mild anti-inflammatory action, whose mechanism is associated with inhibition of prostaglandin synthesis.

Diphenhydramine has anti-allergic and anti-edema effects. It reduces vascular permeability, eliminates nasal mucous membrane edema and hyperemia, sore throat and manifestations of allergic reactions in the upper respiratory tract.

Calcium gluconate is a regulator of calcium and phosphorus metabolism, it has anti-allergic effect (mechanism is not clear), reduces vascular permeability. In allergic diseases or conditions its combined use with antihistamines is recommended.

Pharmacokinetics

There are no data on the pharmacokinetics of Antigrippin-ANVI.

Indications

Colds, Runny nose (rhinitis), Nasal mucous membrane swelling, Myalgia (muscle pain), Fever, Sneezing, Joint pain (arthralgia), SARS, Flu

Symptomatic treatment of flu, SARS, colds in adults and teenagers over 15 years.

Active ingredient

Ascorbic acid, Acetylsalicylic acid, Rutoside, Sodium Metamizole, Calcium Gluconate, Diphenhydromi

Composition

1 A capsule contains:

The active ingredients:

acetylsalicylic acid – 250 mg,

ascorbic acid – 300 mg,

rutoside – 20 mg.

The capsules are of two types.

A hard gelatin capsules, size 0, green; the contents of capsules A – a mixture of crystalline and amorphous powder from light yellow to yellow with a greenish tint, the presence of lumps is possible (10 pcs. in a cellular contour pack).

Excipients:

calcium stearate – 1 mg,

potato starch – 9 mg.

Composition of hard gelatin capsules:

gelatin – 90.723 mg, dye azorubin (E122) – 0.003 mg, dye diamond black (E151) – 0.184 mg, proprietary blue dye (E131) or diamond blue dye (E133) – 0.315 mg, quinoline yellow dye (E104) – 2.207 mg, titanium dioxide (E171) – 2.56 mg.

Delta B capsules are hard gelatin, size 0, white; contents of B capsules are powder and/or granules, white or white with yellowish tint, some lumps are possible (10 pieces in shrink-wrap carton).

Excipients:

calcium stearate – 3.8 mg,

potato starch – 6.2 mg.

The composition of hard gelatin capsules:

gelatin – 91.944 mg, titanium dioxide (E171) – 4.055 mg.

How to take, the dosage

The drug is prescribed to adults and adolescents over 15 years of age 2 capsules per administration: 1 green capsule and 1 white capsule.

The duration of use is 3-5 days until the symptoms disappear.

The capsules are taken orally 2-3 times a day after a meal with water.

Patients should be told that if they do not feel better, the medication should be stopped and they should see a doctor.

Interaction

The effect of heparin, indirect anticoagulants, reserpine, steroid hormones and hypoglycemic drugs in concomitant use with Antigrippin-ANVI is increased.

The efficacy of spironolactone, furosemide, antihypertensive and uricosuric agents is reduced when used concomitantly with Antigrippin-AANVI.

Antigrippin-ANVI increases the adverse reactions of GCS, sulfonylurea derivatives, methotrexate, non-narcotic analgesics and NSAIDs.

In concomitant use of Antigrippin-ANVI with barbiturates, antiepileptics, zidovudine, rifampicin and ethanol-containing drugs the risk of hepatotoxic effects increases. These combinations should be avoided.

Ascorbic acid improves intestinal absorption of iron preparations.

Tricyclic antidepressants, oral contraceptives and allopurinol impair metabolism of metamizole in the liver and increase its toxicity.

Sodium metamizole increases the effects of alcoholic beverages.

The concomitant use of sodium metamizole with cyclosporine reduces the plasma level of the latter.

Concomitant use of sodium metamizole with thiamazole and melphalan increases the risk of leukopenia.

Sedatives and tranquilizers increase the analgesic effect of sodium metamizole.

Rentgen contrast agents, colloidal blood substitutes and penicillin should not be used during the use of sodium metamizole.

Special Instructions

Long-term use of the drug requires monitoring of peripheral blood count and laboratory indicators of liver function.

As acetylsalicylic acid has an antiplatelet effect, the patient, if he/she is to undergo surgery, should warn the physician about taking the drug in advance.

Acetylsalicylic acid at low doses reduces uric acid excretion, which can sometimes lead to gout attacks.

Patients should avoid alcoholic beverages while taking this medication because of the increased risk of gastrointestinal bleeding.

Acetylsalicylic acid has teratogenic effect: when used in the first trimester of pregnancy it causes development of cleft palate; in the third trimester it leads to premature closure of the fetal arterial duct, causing pulmonary hyperplasia and hypertension in the vasculature circulation, and to inhibition of labor activity (because of inhibition of prostaglandin synthesis).

Acetylsalicylic acid is excreted with breast milk, which increases the risk of bleeding in the baby due to platelet dysfunction.

Because of the stimulating effect of ascorbic acid on the synthesis of corticosteroid hormones, renal function and BP should be monitored.

Prescribing ascorbic acid to patients with rapidly proliferating and intensely metastatic tumors may worsen the course of the process.

As a reducing agent, ascorbic acid can distort the results of various laboratory tests (determination of glucose, bilirubin, and plasma “liver” transaminases and LDH activity).

In patients with bronchial asthma and pollinosis, when taking the drug, hypersensitivity reactions may develop.

Impact on driving and operating machinery

When using the drug, one should refrain from performing potentially hazardous activities requiring increased attention and quick psychomotor reactions.

Contraindications

• Gastrointestinal ulcers (acute phase).
• Gastrointestinal bleeding.
• Elevated tendency to bleeding.
• Bronchial asthma and diseases accompanied by bronchospasm (including “aspirin” asthma).
• Inhibition of hematopoiesis (agranulocytosis, neutropenia, leukopenia).
• Hemorrhagic diathesis (hemophilia, Willebrand disease, telangiectasia, hypoprothrombinemia, thrombocytopenia, thrombocytopenic purpura).
• Vitamin K deficiency.
• Severe liver dysfunction.
• Portal hypertension.
• Severe renal dysfunction.
• Hereditary hemolytic anemia (including that associated with glucose-6-phosphate dehydrogenase deficiency).
• Aortic dissection aneurysm.
• Hypercalcemia (calcium ion concentration should not exceed 12 mg% or 6 mEq/L).
• Hypercalciuria.
• Nephrolithiasis (calcium).
• Sarcoidosis.
• Glycoside intoxication (risk of arrhythmia).
• Glucose-6-phosphate dehydrogenase deficiency.
• Pregnancy.
• Lactation (breastfeeding).
• Children and adolescents under 15 years.
• High sensitivity to the components of the drug.

With caution: the drug is prescribed in cases of hyperuricemia, urate nephrolithiasis, gout, peptic ulcer (in anamnesis), decompensated heart failure.

Side effects

Digestive system disorders

Anorexia, nausea, vomiting, gastralgia, diarrhea, gastrointestinal erosive ulcers, gastrointestinal bleeding, liver failure.

Cardiovascular system disorders

Elevated BP, tachycardia .

Allergic reactions

Skin rash, Quincke’s edema, bronchospasm (if prone to bronchospasm, there may be provocation of an attack).

Side effects reported with prolonged use of the drug (more than 7 days)

Blood system disorders: Thrombocytopenia, agranulocytosis, leukopenia.

CNS disorders: Dizziness, headache, visual disturbances, tinnitus, deafness.

With the blood coagulation system: Reduced platelet aggregation, hypocoagulation, hemorrhagic syndrome (including nose bleeding, bleeding gums, purpura).

Allergic reactions: Anaphylactic shock, Stevens-Johnson syndrome, toxic epidermal necrolysis (Lyell’s syndrome).

Urinary system disorders: Renal damage with papillary necrosis, renal dysfunction, oliguria, anuria, proteinuria, interstitial nephritis, urine staining red due to metabolite excretion.

Others: In adolescents – Reye syndrome (hyperpyrexia, metabolic acidosis, nervous system and mental disorders, vomiting, liver function disorders).

The patient must be told that all side effects, including those not mentioned above, must be reported to the physician and the drug stopped.

Overdose

Symptoms of overdose:

• nausea, vomiting, stomach pain, sweating, pale skin, tachycardia; in minor overdose – tinnitus;
• In severe overdose – somnolence, collapse, seizures, bronchospasm, shortness of breath, anuria, bleeding, progressive paralysis of breathing and respiratory acidosis (due to disruption of oxidative phosphorylation).

Treatment:

• artificial vomiting, gastric lavage, prescription of saline laxatives, activated charcoal;
• Intravenous diazepam and barbiturates if seizure syndrome occurs;
• Forced diuresis, hemodialysis if necessary.

.

Pregnancy use

The drug is contraindicated for use during pregnancy. If it is necessary to prescribe during lactation, breastfeeding should be stopped for the period of using the drug.

Acetylsalicylic acid has teratogenic effect: when used in the first trimester of pregnancy it causes development of cleft palate; in the third trimester it leads to premature closure of the fetal arterial duct, causing pulmonary hyperplasia and hypertension in the vasculature circulation, and to inhibition of labor activity (because of inhibition of prostaglandin synthesis).

Acetylsalicylic acid is excreted with breast milk, which increases the risk of bleeding in the baby due to platelet dysfunction.

Preventive use in children

It is contraindicated in children and adolescents under 15 years of age. The drug is not used as an antipyretic in children under 15 years of age with acute respiratory viral diseases due to the risk of Reye syndrome (encephalopathy and acute fatty liver dystrophy with acute development of liver failure).